Trial Profile

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HH 2710 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors ShangHai HaiHe Pharmaceutical

Most Recent Events

19 Jul 2024 The protocol has been Amended to change the primary endpoints of the study and hence the overall trial focus has also been changed to TU and AR.
10 Apr 2023 Status changed from recruiting to discontinued.
12 Apr 2022 Planned End Date changed from 31 Jul 2022 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com